Clinical Proteomics: Rethinking Approaches to Protein Biomarker Discovery

Protein biomarkers are appealing to drug developers because they can be used early in the drug research pipeline, which allows early elimination of ineffective or toxic compounds. Although the promise of these biomarkers is clear, the path to successful implementation of protein biomarkers is not. Perhaps the discovery-based approach is not the best way to tap the potential of protein biomarkers. Get the Answers You Need to Shape Your Strategy Despite scientifi c advancements, protein biomarker discovery is slowing. What are the challenges facing companies and researchers that are hindering the discovery process? Researchers are rethinking the discovery-based approach. What other options and innovations are available? What companies are leading the way? The future of protein biomarkers is extremely promising for a multitude of businesses. What benefi ts are available for technology vendors, Big Pharma companies, researchers, and regulatory agencies? Can collaboration between any or all of these stakeholders ensure the success of protein biomarkers? Please note, the PDF e-mail from publisher version of this report is for a global site license.

Additional Information

Scope
Proteomics technologies: 2D PAGE, mass spectrometry, antibody microarrays, microfl uidics, label-free technologies. Alternatives to discovery-based approach: hypothesis-based approach, engineering better biomarkers, systems biology. Major players in protein biomarker discovery: Bayer, Eli Lilly, Novartis, Pfi zer, Roche.

Outlook: The path toward successful protein biomarker discovery may include multiplexing strategies, collaborations among researchers and developers, and support from regulatory bodies.

Companies Mentioned in This Spectrum Report

Applied Biosystems
Axis Shield
Bayer Pharmaceuticals
Beyond Genomics
Biacore
Bioforce Nanoscience
Bio-Rad
Biosite
Bruker Daltonics
Cantion
Clontech
CODA Genomics
Eisai
Eli Lilly
Fujirebio
Gene News
Genedata
GeneProt
Geneva Proteomics
Genomic Solutions
Genoptics
GenTel Biosciences
Integrated Genomics
Invitrogen
Johnson & Johnson
Lumera
Matritech
Microfl uidics
Millennium Pharmaceuticals
Pfizer
Phadia US
Power3 Medical Products
Predictive Diagnostics
Proteome Systems
Quadraspec
RBM
Roche
Rosetta Inpharmatics
Sareum
Shimadzu
Target Discovery